Clinical trials: Tregs
Systemic Lupus Erythematosus
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).
- Trial name
- ISLAND-SLE (NCT04433585)
- Testing
- LY3471851
- Where
- 112 sites in United States, Argentina and 17 more
- Volunteers
- 291 people
- Sponsor
- Nektar Therapeutics
Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder
Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation
This phase I trial tests the safety, side effects, and best dose of allogeneic CD6 chimeric antigen receptor T regulatory cells (CD6-CAR Tregs) in treating patients who have chronic graft versus host disease (cGVHD) after an…
- Conditions
- Chronic Graft Versus Host Disease, Hematologic and Lymphocytic Disorder, Steroid Refractory Graft Versus Host Disease
- Trial name
- NCT05993611
- Testing
- Biopsy, Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- City of Hope Medical Center
Multiple Sclerosis, Relapsing-Remitting, Adult ALL
Investigating the Effects of Hydroxyvitamin D3 on Multiple Sclerosis
Investigating the effects of hydroxyvitamin D3 on clinical, radiologic and immunomodulatory markers in MS patients: A randomized, clinical trial- a pilot study
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Adult ALL, Vitamin D3 Deficiency
- Trial name
- NCT05340985
- Testing
- 25(OH)D3, vitamin D3
- Volunteers
- 54 people
- Sponsor
- Tehran University of Medical Sciences
Relapsing Remitting Multiple Sclerosis
Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis
Interleukin-2 (IL-2) was initially discovered and used as a stimulator of effector T lymphocytes (Teffs), but is now viewed as a very promising immunoregulatory drug having the capacity to stimulate regulatory T cells (Tregs).
- Trial name
- MS-IL2 (NCT02424396)
- Testing
- IL2
- Where
- 3 sites in France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Liver Transplantation
Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation
The purpose of this study is look at the safety of: Taking a specific combination of immunosuppressant drugs after liver transplantation Receiving one of three different doses of donor-alloantigen-reactive regulatory T cells…
- Trial name
- deLTa (NCT02188719)
- Testing
- Anti-Thymocyte Globulin - Rabbit, darTreg Infusion, Everolimus
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immunosuppression, Kidney Transplantation
The Differential Effects of 3 Different Immunosuppressive
The study is a laboratory investigation comparing the regulatory effects of different immunosuppressive therapies in an in vitro human MLR assay of selecting specific immunosuppressive therapy to promote a regulatory profile and…
- Trial name
- NCT00729248
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Leukemia, Lymphoma
Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention
Any time the words "you," "your," "I," or "me" appear, it is meant to apply to the potential participant. T-cells are white blood cells that are important to the immune system.
- Trial name
- NCT02423915
- Testing
- Rituximab, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Hepatitis C Infection
The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis
Viral hepatitis is a serious world health problem affecting over 1 billion people worldwide. Presently the lack of highly effective treatments results in many patients requiring liver transplantation or death.
- Trial name
- NCT01711164
- Where
- Canada
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
VITILIGO
Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo
This study aims to evaluate some differences in the immune system between patients with vitiligo and patients without the disease.
- Trial name
- NCT03249064
- Testing
- CD 91 levels, Tregs
- Where
- Spain
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
RCC, Metastatic Renal Cell Carcinoma
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy
The project aims to identify Nivolumab predictive biomarkers in metastatic renal cancer patients through functional evaluation of peripheral Tregs and NKs.
- Trial name
- REVOLUTION (NCT03891485)
- Testing
- Immunological and tumour characterization
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- National Cancer Institute, Naples
Henoch Schönlein Purpura
Study of the Role of Regulator T Cells in the Pathophysiology of Childhood Henoch Schönlein Purpura
The primary objective of this study is to search for evidence of quantitative or functional defects in plasma regulatory T cells (Tregs) in pediatric patients with Henoch Schönlein Purpura (HSP) as compared to a control…
- Trial name
- FOX-TREG (NCT02317133)
- Testing
- Blood samples, Stool samples
- Where
- 2 sites in France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid
Autologous Polyclonal Tregs for Lupus
The primary purpose of this Phase 1 study is to evaluate the safety, tolerability, and effect of 3 different doses of Treg therapy in adults with skin (cutaneous) involvement of their lupus.
- Conditions
- Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
- Trial name
- NCT02428309
- Testing
- Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Immune Tolerance, Food Tolerance
Tregs and miRNAs in Breast Milk: Effects on Infant Food Tolerance
This prospective observational study aims to identify and characterize immunoregulatory microRNAs (miRNAs) associated with regulatory T cells (Tregs) in human breast milk and to evaluate their temporal expression patterns.
- Trial name
- NCT07744373
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Istanbul University
Stage 3 Type 1 Diabetes
Autologous CD6-CAR Treg Cells for Patients With Stage 3 Type 1 Diabetes
Type 1 diabetes (T1D) is a persistent and gradually increasing genetic autoimmune disease requiring life-long management. The disease commonly impacts children. However, a quarter of cases are diagnosed in adults.
- Trial name
- NCT07395050
- Testing
- AutoCD6-CAR Treg cells
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- City of Hope Medical Center
Colitis, Ulcerative
A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)
The reason for this study is to determine if the study drug LY3471851 is safe and effective in adult participants with active ulcerative colitis (UC). The study treatment will last about 52 weeks.
- Trial name
- INSTRUCT-UC (NCT04677179)
- Testing
- LY3471851
- Where
- 116 sites in United States, Argentina and 20 more
- Volunteers
- 81 people
- Sponsor
- Nektar Therapeutics
Aplastic Anemia
Autologous Tregs for Aplastic Anaemia
This Phase I study will determine the safety and optimal dose of expanded autologous Tregs to treat patients with Aplastic Anaemia (AA) (who have failed, or are considered ineligible for IST (immunosuppressive therapy) / other…
- Trial name
- TIARA (NCT05386264)
- Testing
- Expanded autologous T regulatory cells
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- King's College Hospital NHS Trust
Aplastic Anemia
CK0801 for Treatment of Aplastic Anemia
This Phase 2, multicenter, open-label study is evaluating CK0801 for the treatment of aplastic anemia in adults with persistent transfusion dependence after at least one prior line of therapy or intolerance to standard-of-care…
- Trial name
- NCT07499102
- Testing
- CK0801
- Volunteers
- 12 people
- Sponsor
- Cellenkos, Inc.
Metastatic Colorectal Cancer
Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients
Aim of the present study is to investigate whether baseline or early post-treatment (one month after treatment commencement) frequency of peripheral T regulatory lymphocytes (Tregs OR CD4+/CD25high/FOXP3+ T cells), known to…
- Trial name
- NCT01533740
- Testing
- fluorouracil/irinotecan/levo-folinic acid/bevacizumab
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- University of Rome Tor Vergata
Conjunctivitis, Allergic
Treg Effector Function and Th2/Treg Ratio in Allergic Conjunctivitis: Effect of Desensitization Therapy
This study aims to evaluate the effector function and expression of TIGIT and PD-1 on Tregs, as well as the Th2/Treg ratio, in patients with allergic conjunctivitis with and without desensitization therapy, compared to healthy…
- Trial name
- INMUNOREG (NCT07171307)
- Where
- Mexico
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Instituto de Oftalmología Fundación Conde de Valenciana
Ovarian Cancer
Ovarian Dendritic Cell Vaccine Trial
The purpose of this study is to determine if a dendritic cell vaccine made with autologous tumor lysate or for patients who are HLA-A2 with peptides of MUC1 and WT1 therapy will produce remissions in patients with advanced…
- Trial name
- NCT00703105
- Testing
- DC vaccination
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Loyola University